Saturday, July 11, 2026

biotech · Propionic Acidemia · Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency

SOM Biotech

Moderna Biotech Spain is a biotech organization headquartered in EU. Primary therapeutic focus areas include Propionic Acidemia, Isolated Methylmalonic Acidemia Due to Methylmalonyl-CoA Mutase Deficiency, Glycogen storag

Barcelona, ES HQ
2009 Founded
14 Employees
EMA registrant Type
Company details
Clinical program

mRNA-1010

Phase 3 · mab · Seasonal Influenza

mRNA-1010 for Seasonal Influenza is a Phase 3 program (mab) at Moderna Biotech Spain with 1 ClinicalTrials.gov record(s).

Internal code mRNA-1010-P301

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Moderna Biotech Spain
Phase
Phase 3
Modality
mab
Indication
Seasonal Influenza
Status
completed
Trials
1